[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-460612-105":59,"doc-detail-460612-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","thinking-beyond-the-tablet-acceptability-of-different-hiv-prep-modalities-among-gbmsm-and-gender-diverse-individuals-having-sex-with-men-in-the-uk","Thinking beyond the tablet - Acceptability of different HIV-PrEP modalities among GBMSM and gender-diverse individuals having sex with men in the UK","","HIV-PrEP is presented as a key element of HIV combination prevention, available in the UK since 2020 via oral formulations. The study analyzes data from the large online RiiSH community survey of 1106 GBMSM and gender-diverse individuals in November–December 2023 to evaluate acceptability and preferences across oral, long-acting injectable, gel, or patch modalities by prior HIV-PrEP experience.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/thinking-beyond-the-tablet-acceptability-of-different-hiv-prep-modalities-among-gbmsm-and-gender-diverse-individuals-having-sex-with-men-in-the-uk/460612/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/thinking-beyond-the-tablet-acceptability-of-different-hiv-prep-modalities-among-gbmsm-and-gender-diverse-individuals-having-sex-with-men-in-the-uk/460612.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study evaluate about HIV-PrEP modalities?","Question",{"text":112,"@type":113},"It assesses acceptability and preference across oral, long-acting injectable, gel, and patch modalities among GBMSM and gender-diverse individuals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was participant data collected and analyzed?",{"text":117,"@type":113},"Data came from the RiiSH 2023 online community survey (November–December 2023). Secondary analysis was performed using participants’ responses and HIV-PrEP history.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on acceptability and preference?",{"text":121,"@type":113},"Long-acting injectables were highly acceptable (>70%) regardless of prior HIV-PrEP history, and they were generally preferred over oral tablets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},460612,1791182938,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Original research article  \nThinking beyond the tablet: Acceptability of different HIV-PrEP modalities among GBMSM and gender-diverse individuals having sex with men in the UK  \nDana Ogaz 1,2 􀀁, Natasha Ratna1, Hridhya Vijayan 1 􀀁, Stephanie J Migchelsen 1 􀀁, David Reid2,3, Dolores Mullen 1 􀀁, Dawn Phillips1, Eleanor Bell 1, Tamara Djuretic 1, Will Nutland4, Catherine H Mercer2,3, Kate Folkard 1, John Saunders 1,2,3 􀀁 and Hamish Mohammed 1,2,3 􀀁  \nInternational Journal of STD & AIDS 2026, Vol. 37(1) 30–35  \n© The Author(s) 2025  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/09564624251369093](DOI: 10.1177/09564624251369093)[ ](DOI: 10.1177/09564624251369093)[journals.sagepub.com/home/std](journals.sagepub.com/home/std)  \nAbstract  \nBackground: HIV-PrEP is a key component of HIV combination prevention and has been routinely available through oral formulations (i.e. oral tablets) across sexual health services (SHSs) in the UK since 2020. We used data from a large, online community survey to assess the acceptability and preference of different HIV-PrEP modalities among gay, bisexual, and other men who have sex with men (GBMSM) and gender-diverse individuals living in the UK.  \nMethods: Using data collected from the ‘Reducing inequalities in Sexual Health’ (RiiSH) survey, an online community survey of 1106 GBMSM and gender-diverse individuals having sex with men (November/December 2023), we performed a secondary analysis examining HIV-PrEP modality acceptability and preference (e.g. oral, long acting injectable, gel, or patch) (%) by HIV-PrEP history (never, in lookback period of last 3–4 months since survey completion). Where ≥2 modalities were indicated, participants were asked to specify a single preferred modality. Single choice options were assumed to be the preferred HIV-PrEP modality.  \nResults: Irrespective of HIV-PrEP history, long acting injectables were highly acceptable (>70%) and the preferred modality (58%[222/386] by those never having used HIV-PrEP, 73%[75/103] in those without HIV-PrEP use in the lookback, 74%[314/424] in those with HIV-PrEP use in the lookback).  \nConclusions: We found high acceptability of the use of injectables, with general preference over oral tablets. If injectable HIV-PrEP becomes available at SHSs in England, these modalities could have positive impacts on HIV-PrEP delivery, use, and access.  \nKeywords  \nHIV (Human immunodeﬁciency virus), viral disease, prevention, other, homosexual, other, men, other  \nBackground  \nIn England, HIV disproportionately affects gay, bisexual, and men who have sex with men (GBMSM), who represented nearly a third of new HIV diagnoses in 2023 despite comprising a minority (\u003C5%) of the population.1,2  \nAlongside scale-up of repeat HIV testing and immediate antiretroviral treatment (ART) as prevention,3,4 HIV-PrEP comprises a key component of HIV combination prevention. Since the start of routine commissioning in 2020, over 80,000 individuals, primarily GBMSM, have accessed HIV-PrEP through sexual health services (SHSs) in  \n1 Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK  \n2 The National Institute for Health and Care Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in Partnership with the UK Health Security Agency, London, UK  \n3 Institute for Global Health, University College London, London, UK  \n4 The Love Tank, London, UK  \nCorresponding author:  \nDana Ogaz, The National Institute for Health and Care Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK.  \nEmail: [d.ogaz@ucl.ac.uk](d.ogaz@ucl.ac.uk)  \nEngland.1 At present, HIV-PrEP is dispensed across SHSs in tablet form for daily or event-driven use, with quarterly (or at least 6-mon","cbCailZBOBgFqYIB","https://ap.wps.com/l/cbCailZBOBgFqYIB","pdf",587959,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n# Methods\n## Data collection and recruitment\n## HIV-PrEP modality acceptability and preference among RiiSH 2023 participants","[{\"question\":\"What does the study evaluate about HIV-PrEP modalities?\",\"answer\":\"It assesses acceptability and preference across oral, long-acting injectable, gel, and patch modalities among GBMSM and gender-diverse individuals.\"},{\"question\":\"How was participant data collected and analyzed?\",\"answer\":\"Data came from the RiiSH 2023 online community survey (November–December 2023). Secondary analysis was performed using participants’ responses and HIV-PrEP history.\"},{\"question\":\"What were the key findings on acceptability and preference?\",\"answer\":\"Long-acting injectables were highly acceptable (\\u003e70%) regardless of prior HIV-PrEP history, and they were generally preferred over oral tablets.\"}]","Thinking beyond the tablet - Acceptability of different HIV-PrEP modalities among GBMSM and gender-diverse individuals having sex with men in the UK | PDF",1790758885,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/83e78fac1ac64b74d10d84044e3e792a.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ac78a3bd08cb94c9f9855b995b4c8460.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/0be598d6215e03f41a283f46c23bdff2.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/02dce7c37db346fda6b285692cc51fb4.webp",980,1306]